CYFRA 21-1: an indicator of survival and therapeutic effect in lung cancer

Oncology
Y TakeiM Mori

Abstract

CYFRA 21-1 is a new tumor marker using two different monoclonal antibodies which recognize the divergent epitope on the N- or C-terminal region of domain 2 of cytokeratin 19 fragment, respectively. In this study, we investigated the relationship between levels of CYFRA 21-1 and survival duration, as well as the efficacy of chemotherapy associated with changes in CYFRA 21-1. Serum samples were obtained from 87 patients with nonoperable lung cancer (35 cases with squamous-cell carcinoma, 33 with adenocarcinoma, 3 with large-cell carcinoma, and 16 with small-cell carcinoma). The cutoff point was set at 3.5 ng/ml. In a CYFRA 21-1 assay, significantly more patients with squamous-cell carcinoma and adenocarcinoma were positive compared to patients with small-cell and large-cell carcinomas (p = 0.0017). Following chemotherapy, blood levels of CYFRA 21-1 decreased significantly in responders versus nonresponders (p = 0.0246). A significant correlation was noted between survival periods and pretreatment levels of CYFRA 21-1 (p = 0.0036). The present study suggests that CYFRA 21-1 might be useful as a possible indicator of survival and therapeutic effect for lung cancer.

Citations

May 19, 2006·Journal of Hepato-biliary-pancreatic Surgery·Takahiro UenishiShoji Kubo
Oct 31, 2002·Cancer Practice·Maureen J AngenMarilyn Hundleby
Jul 23, 2002·Human Gene Therapy·Pasquale CironePatricia L Chang
Oct 29, 2005·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Rafael MolinaPetra Stieber
Oct 24, 2007·Annals of Surgical Oncology·Takahiro UenishiShoji Kubo
Jul 6, 2004·Clinical Biochemistry·S Holdenrieder, P Stieber

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.